Zacks.com on MSN6d
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...
pharmaphorum5d
Novartis licenses lipoprotein-lowering CVD drug
The firm already markets recently-approved Entresto (sacubitril+valsartan) to treat heart failure, and diabetes drug Galvus (vildagliptin) through its cardio-metabolic division, and is looking to ...
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from ...
Novartis Pharma AG: Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...
Medscape2d
Dipeptidyl Peptidase-4 Inhibitors: Clinical Data and Clinical Implications
The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...